Preparation and optimization of N-trimethyl-O-carboxymethyl chitosan nanoparticles for delivery of low-molecular-weight heparin

References

• Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:22–30
   PubMed Web of Science ®Google Scholar
• Agnelli G, Prandoni P, Santamaria MG, et al. The Warfarin Optimal Duration Italian Trial Investigators: three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165–169
   PubMed Web of Science ®Google Scholar
• Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382–2389
   PubMed Web of Science ®Google Scholar
• Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002;25:447–454
   PubMed Web of Science ®Google Scholar
• Hirsh J. Heparin. N Engl J Med 1991;324:1565–1574
   PubMed Web of Science ®Google Scholar
• Arbit E, Goldberg M, Orellana IG, Majuru S. Oral Heparin: status review. Thoromobosis J 2006;24:236–245
   Google Scholar
• Kotzé AF, Luessen HL, De Leeuw BJ, et al. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Contl Rel 1998;51:35–46
   PubMed Web of Science ®Google Scholar
• Ward PD, Tippin TK, Thakker DR. Enhancing the cient absorption enhancer of peptide drugs. Paracellular permeability by modulating epithelial tightjunctions. Pharm Sci Technol Today 2000;3:346–358
   PubMedGoogle Scholar
• Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol 1998;284:362–369
   Google Scholar
• Suh JKF, Matthew HWT. Application of chitosan based solution (protonated), is able to interact with the polysaccharide biomaterials in cartilage tissue engineering. A review. Biomaterials 2000;21:2589–2598
   PubMed Web of Science ®Google Scholar
• Kumar MNVR. A review of chitin and chitosan applications. Reactive Funct Polymers 2000;46:1–27
   Web of Science ®Google Scholar
• Dodane V, Vilivalam VD. Pharmaceutical applications of the epithelium or the cell membranesare minimal chitosan. Pharm Sci Technol Today 1998;1:246–253
   Google Scholar
• Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998;15:1326–1331
   PubMed Web of Science ®Google Scholar
• Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal at neutral pH values can be tackled by derivatization delivery system for peptide drugs. Pharm Res 1994;11:1186–1189
   PubMed Web of Science ®Google Scholar
• Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int J Pharm 1994;111:213–216
   Web of Science ®Google Scholar
• Kotze Awie F, Luessen Henrik L, De-Leeuw Bas J, et al. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells Caco-2. J Control Release 1998;51:35–46
   PubMed Web of Science ®Google Scholar
• Ibrahim H, Bindschaedler C, Doelker E, et al. Aqueous nanodispersions prepared by a salting-out process. Int J Pharm 1992;87:239–246
   Web of Science ®Google Scholar
• Leroux JC, Allemann E, Doelker E, Gurny R. New approach for the preparation of nanoparticlesby an emulsification-diffusion method. Eur J Pharm Biopharm 1995;41:14–18
   Web of Science ®Google Scholar
• Xua T, Xina M, Li M. Synthesis, characteristic and antibacterial activity of N,N,N-trimethyl chitosanand its carboxymethyl derivatives. Carbohydr Res 2011;346:2445–2459
   PubMed Web of Science ®Google Scholar
• Liu XF, Guan YL, Yang DZ, et al. Antibacterial Action of chitosan and carboxymethylated chitosan. J Appl Polymer Sci 2001;79:1324–1335
   Web of Science ®Google Scholar
• Shahsavari S, Bagheri G, Mahjub R, et al. Application of artificial neural networks for optimization of preparation of insulin nanoparticles composed of quaternized aromatic derivatives of chitosan. Drug Res (Stuttg) 2014;64:151–158
   PubMedGoogle Scholar
• Rawat A, Yang T, Hussain A, Ahsan F. Complexation of a poly-l-arginine with low molecular weight heparin enhances pulmonary absorption of the drug. Pharm Res 2008;25:936–948
   PubMed Web of Science ®Google Scholar
• Mahjub R, Dorkoosh FA, Amini M, et al. Preparation, statistical optimization, and in vitro characterization of insulin nanoparticles composed of quaternized aromatic derivatives of chitosan. AAPS Pharm Sci Tech 2011;12:1407–1401
   PubMed Web of Science ®Google Scholar
• Mao S, Bakowsky U, Jintapattankit A, Kiessel T. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J Pharm Sci 2006;95:1035–1048
   PubMed Web of Science ®Google Scholar
• Nasti A, Zaki NM, De Leonardis P, et al. Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res 2009;26:1918–1930
   PubMed Web of Science ®Google Scholar
• Giannotti MI, Esteban O, Oliva M, et al. pH-responsive polysaccharide-based polyelectrolyte complexes\ as nanocarriers for lysosomal delivery of therapeutic proteins. Biomacromolecules 2011;12:2524–2533
   PubMed Web of Science ®Google Scholar
• Muzzarelli RA, Barontini G, Rocchetti R. Immobilized enzymes on chitosan columns: alpha-chymotrypsin and acid phosphatase. Biotech Bioeng 1976;18:1445–1454
   PubMed Web of Science ®Google Scholar
• Di Colo G, Zambito Y, Zaino C. Polymeric enhancers of mucosal epithelia permeability: syhthesis, trans epithelial penetration enhancing properties, mechanism of action, safety issues. J Pharm Sci 2008;97:1652–1680
   PubMed Web of Science ®Google Scholar
• Mahjub R, Radmehr M, Dorkoosh FA, et al. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations. Drug Dev Ind Pharm 2013 Oct 04 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Wang L, Li L, Sun Y, et al. In vitro and in vivo evaluation of chitosan graft glyceryl monooleate as peroral delivery carrier of enoxaparin. Int J Pharm 2014;471:391–399
   PubMed Web of Science ®Google Scholar
• Bagre AP, Jain K, Jain NK. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Int J Pharm 2013;456:31–40
   PubMed Web of Science ®Google Scholar
• Wang L, Li L, Sun Y, et al. Exploration of hydrophobic modification degree of chitosan-based nanocomplexes on the oraldelivery of enoxaparin. Eur J Pharm Sci 2013;50:263–271
   PubMed Web of Science ®Google Scholar
• Thanou M, Nihot MT, Jansen M, et al. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci 2000;90:38–46
   Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 2001;52:117–126
   PubMed Web of Science ®Google Scholar